Home » ThromboGenics Resubmits BLA for Ocriplasmin With the FDA
ThromboGenics Resubmits BLA for Ocriplasmin With the FDA
ThromboGenics announced that it has resubmitted a biologics license application with the FDA for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic Vitreomacular Adhesion including macular hole.
MarketWatch
MarketWatch
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May